Trading Systems Reacting to (OMCL) Volatility
Omnicell Inc. (NASDAQ: OMCL) is exhibiting a neutral sentiment across all time horizons, indicating a wait-and-see approach. The AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis also highlights an exceptional 76.9:1 risk-reward setup, targeting a 21.7% gain against a 0.3% risk.
Omnicell, Inc. Bonds — Corporate Bond Rates
This article provides a list of corporate bonds for Omnicell, Inc., sorted by yield to worst, aimed at investors looking for stability. It details one specific bond (OMCL6251486) with a 1.0% coupon rate maturing on December 1, 2029, and its outstanding amount and face value. The information is presented through TradingView, emphasizing the reliability of corporate bonds in volatile markets.
Cost of goods sold of Omnicell, Inc. – HAN:OC9
This article displays the "Cost of goods sold" for Omnicell, Inc. (HAN:OC9) on the TradingView platform. It provides a quick financial snapshot, indicating the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet.
Omnicell stock reports 7.40 percent revenue growth in Q2 2026
Omnicell (OMCL) reported a 7.40 percent year-over-year revenue growth in Q2 2026, reaching USD 312.20 million, which exceeded analyst estimates. The company's EPS was USD 0.94, significantly higher than the consensus of USD 0.47. Despite strong Q2 results, the stock is trading below its yearly high, and Q3 2026 EPS guidance is set lower, highlighting the importance of execution in its medication-cabinet refresh cycle.
Omnicell stock trades 39.95 percent below its yearly high
Omnicell stock is trading significantly below its 52-week high despite strong Q2 2026 financial results, including a 7.4% revenue increase and an EPS beat. The company has a fiscal 2026 consensus EPS estimate of USD 2.15, with analysts revising forecasts upwards. Omnicell is pursuing a product refresh, but its stock price remains closer to its yearly low.
Why Omnicell (OMCL) Shares Moved And What Investors Are Watching
Omnicell (OMCL) shares have seen recent movement, closing at $33.17, following a period of mixed returns. While recent trading shows a small rebound, the stock has declined over the last 30 days and year-to-date. The article highlights that Omnicell is viewed by many as 46% undervalued with a fair value of $61.29, driven by its OmniSphere platform and transition to SaaS revenues, but also cautions about risks like tariff costs and hospital budget tightening.
(OMCL) Volatility Zones as Tactical Triggers
This article analyzes Omnicell Inc. (NASDAQ: OMCL) using AI models, identifying a neutral near-term sentiment with potential for moderate mid-term weakness. It highlights an exceptional 78.7:1 risk-reward setup targeting a 21.8% gain versus 0.3% risk, and provides three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
3 Reasons OMCL is Risky and 1 Stock to Buy Instead
This article analyzes Omnicell (OMCL) and concludes it is a risky investment due to disappointing long-term revenue growth, declining EPS, and ineffective growth initiatives. The author suggests investors look for alternative opportunities, recommending a specific software stock and offering a free list of top stock picks from their AI system.
Omnicell stock holds steady as investors await next earnings update
Omnicell stock closed at USD 32.62 on September 18, 2026, showing a slight increase. The consensus EPS for the upcoming report is USD 0.42, a 17.7% decline from the previous year, indicating lower profitability expectations. Analysts currently rate Omnicell with a "Hold" due to neutral near-term performance expectations and a recent negative 11% return over the past month.
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating
Craig-Hallum has reiterated its Buy rating on Omnicell (OMCL.US). This indicates a continued positive outlook from the investment firm regarding the company's stock.
TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
TraceLink and Omnicell have integrated TraceLink's DSCSA compliance solution with Omnicell's pharmacy inventory management systems to streamline medication receiving workflows in hospitals. This integration aims to embed product verification, traceability, and compliance directly into daily operations, reducing manual effort and improving efficiency for pharmacy teams. The collaboration helps hospitals verify serialized medicines, resolve compliance exceptions, and enhance traceability for patient safety and regulatory adherence.
TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
TraceLink and Omnicell have integrated TraceLink's DSCSA compliance solution into Omnicell's pharmacy inventory management systems. This integration aims to streamline medication receiving workflows in hospitals, allowing for serialized product verification, traceability, and compliance reporting directly within existing operations. The goal is to reduce manual effort, improve efficiency, and ensure faster access to authenticated medicine information for patient care.
A new integration lets hospitals check medicines as they arrive
Omnicell and TraceLink have integrated TraceLink's DSCSA compliance solution directly into Omnicell's central pharmacy inventory management workflows. This integration allows hospitals to streamline medication verification, traceability, and compliance reporting, reducing manual effort and improving efficiency. The goal is to ensure quicker access to accurate serialized medicine data, supporting faster recall responses and overall patient safety.
Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
Omnicell, Inc. announced it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 12:45 p.m. EDT. Live and archived webcasts of the presentation will be available through the company's website. Omnicell is a leading healthcare technology provider focused on autonomous medication management, aiming to improve efficiency and enhance patient safety worldwide.
Is Omnicell Inc (OMCL) a Bargain After 4.2% Drop? GF Value Says Undervalued
Omnicell Inc (OMCL) shares dropped 4.2% to $33.21, placing it 12.9% below its GF Value™ of $38.15, suggesting it is undervalued. Despite a solid GF Score™ of 78/100 and favorable valuation metrics compared to historical data, insider selling of $3.2M without purchases raises caution for potential investors. Gurus, however, show a generally positive sentiment with most increasing their positions.
KeyBanc reiterates Omnicell stock rating on large pipeline growth
KeyBanc has reiterated its Overweight rating and $65.00 price target for Omnicell (NASDAQ:OMCL) after executive meetings. The firm noted that Omnicell's pipeline is the largest in years and continues to grow, with its Omnisphere product resonating well with customers. Despite recent Q2 2026 outperformance in earnings and revenue, the stock declined premarket due to concerns over softer bookings guidance and a near-term outlook, alongside reliance on a one-time tariff refund.
KeyBanc reiterates Omnicell stock rating on large pipeline growth By Investing.com
KeyBanc has reiterated its Overweight rating and $65.00 price target for Omnicell (NASDAQ:OMCL) after meetings with company executives, citing significant pipeline growth and the company's financial strength. Despite concerns over softer bookings guidance and a lower near-term outlook that caused a premarket stock decline following Q2 2026 results, KeyBanc believes widened bookings guidance reflects deal timing rather than weakening demand. The firm also highlighted Omnicell's strong Piotroski Score of 9 and expected net income growth, with its Omnisphere product resonating well with customers.
Trillium Asset Management LLC Buys New Position in Omnicell, Inc. $OMCL
Trillium Asset Management LLC has acquired a new position in Omnicell, Inc. (NASDAQ:OMCL), purchasing 115,990 shares valued at approximately $4.8 million. This move is part of a broader trend where institutional investors have increased their holdings, now owning 97.7% of the company. Despite mixed analyst sentiment and a recent downgrade by Zacks, Omnicell exceeded quarterly earnings expectations, reporting $0.94 EPS against a $0.47 consensus, and maintained its 2026 full-year guidance.
Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have issued a "Moderate Buy" consensus recommendation for Omnicell, Inc. (NASDAQ:OMCL), with an average 12-month price target of $57.86, significantly higher than its opening price of $35.50. Despite a recent downgrade to "strong sell" by Zacks Research and some lowered price targets from other firms, Omnicell exceeded its latest quarterly earnings and revenue expectations. However, Zacks has also reduced near-term and 2027 earnings estimates, indicating a cautious outlook despite past performance.
Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL
Bank of America Corp DE significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 31.3% in the first quarter, now holding 580,875 shares valued at $19.39 million. This move comes as institutional investors collectively own 97.7% of the company. Despite positive analyst sentiment with a "Moderate Buy" consensus, recent price target reductions and mixed earnings forecasts indicate a cautious outlook for Omnicell's stock performance.
Zacks Research Has Bearish Estimate for Omnicell Q3 Earnings
Zacks Research has issued a "Strong Sell" rating for Omnicell (NASDAQ:OMCL) and reduced its Q3 2026 EPS estimate to $0.25 from $0.27. Despite the near-term bearish outlook, Zacks projects a full-year 2026 EPS of $1.49, exceeding the broader consensus, but has lowered its FY2027 forecast to $1.27. Institutional investors hold a significant 97.7% stake in the company, which recently reported better-than-expected earnings and revenue for its latest quarter.
Rice Hall James & Associates LLC Invests $2.15 Million in Omnicell, Inc. $OMCL
Rice Hall James & Associates LLC has invested approximately $2.15 million in Omnicell, Inc. (NASDAQ:OMCL) by acquiring 51,789 shares, representing about 0.11% of the company. Omnicell has garnered a "Moderate Buy" rating from analysts with an average target price of $57.86, despite some recent price target adjustments. The company recently surpassed quarterly earnings expectations, reporting $0.94 EPS against a $0.47 consensus and revenue of $312.21 million.
Omnicell (OMCL) Slides On Valuation Debate, Is The Stock Cheap?
Omnicell (OMCL) has seen its share price decline significantly over the past month, leading to a debate about its valuation. While some analyses suggest it is undervalued with a fair value of $61.29 based on its shift to recurring SaaS revenue, others point to its high P/E ratio of 42.1x compared to industry averages, indicating potential overvaluation. Investors are encouraged to review underlying numbers and consider risks before making investment decisions.
Omnicell (OMCL) Slides On Valuation Debate, Is The Stock Cheap?
Omnicell (OMCL) has seen its share price fall by 21% in the past month and 18% over the last three months, raising questions about its valuation. While analyst narratives suggest the stock is undervalued with a fair value of $61.29 due to its OmniSphere platform's shift to recurring SaaS revenues, its current P/E ratio of 42.1x is higher than the industry average, implying potential valuation risk. Investors are advised to examine the underlying numbers and consider both potential rewards and risks.
Omnicell (NASDAQ: OMCL) CEO withholds stock to cover RSU taxes
Omnicell's Chairman and CEO, Randall A. Lipps, reported withholding 12,350 shares of Common Stock at $37.30 on August 15, 2026, to cover tax obligations from vesting restricted stock units. Following this transaction and an Employee Stock Purchase Plan acquisition, Lipps directly holds over 511,000 shares and indirectly holds additional shares in trusts. This event is categorized as a neutral insider transaction with moderate filing impact.
Omnicell (OMCL) legal chief has 4,025 shares withheld for taxes
Omnicell's Executive Vice President and Chief Legal/Administrative Officer, Corey J. Manley, had 4,025 shares of common stock withheld to cover taxes related to the vesting of restricted stock units on August 15, 2026. The reference price for these shares was $37.30. Following this transaction and an additional purchase of 226.4621 shares through an Employee Stock Purchase Plan, Manley now directly holds 108,984.8013 shares of Omnicell common stock.
Omnicell (NASDAQ: OMCL) exec holds 22,265.8924 shares after tax move
Brian H. Nutt, VP and Chief Accounting Officer of Omnicell (NASDAQ: OMCL), had 937 shares withheld at $37.30 each on August 15, 2026, to cover taxes on vested restricted stock units. Following this, his direct holdings total 22,265.8924 shares. The balance also reflects an additional 343.2789 shares purchased through the company's Employee Stock Purchase Plan on the same day.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has increased its 2026 earnings outlook after a strong second quarter, although a significant portion of this improvement was due to a one-time tariff refund. The company faces future challenges from rising memory-chip costs, which are expected to impact gross margins. Omnicell's ability to maintain profitability will depend on its operating discipline, cost control, and the timing of hospital purchasing decisions, particularly as its Zacks Rank currently indicates a "Strong Sell."
Omnicell (NASDAQ: OMCL) insider plans sale of 3,083 shares
Omnicell insider Nnamdi T. Njoku has filed a notice of intent to sell 3,083 shares of common stock, valued at $113,608.55, through Fidelity Brokerage Services LLC. These shares are compensation-related, stemming from restricted stock vesting on August 15, 2026. Njoku previously sold 3,090 shares for $133,549.80 on May 18, 2026.
Omnicell, Inc. $OMCL Shares Acquired by Empowered Funds LLC
Empowered Funds LLC significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4,229.9% in the first quarter, now owning 262,043 shares valued at $8.7 million. This comes as other institutional investors have also adjusted their positions in the healthcare technology company. Insider transactions show Omnicell executives Nnamdi Njoku and Corey J. Manley sold shares to cover tax obligations, while analysts maintain a "Moderate Buy" consensus rating for the stock.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has increased its 2026 earnings outlook after a strong second quarter, partially boosted by a one-time tariff refund. The company faces a $6 million headwind from rising memory-chip costs but plans to offset this with operational discipline and cost control. Despite a "Strong Sell" Zacks Rank, the stock shows favorable growth, value, and momentum characteristics.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control and operating efficiency to absorb these pressures. Omnicell's updated guidance also includes widened product bookings and a reduction in annual recurring revenue expectations due to slower development of certain opportunities and lengthy hospital approval cycles.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell (OMCL) shares have dropped 20.1% in the past month despite raising its 2026 profit outlook, due to concerns over bookings timing, recurring-revenue growth, rising component costs, and the pace of its product refresh. While the company's Q2 2026 earnings beat estimates, new pressures from memory-chip costs and a slower-than-expected refresh cycle are affecting margins and revenue predictability. Despite a low valuation, the Zacks Rank currently signals caution due to short-term uncertainties.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell (OMCL) shares have
Quantinno Capital Management LP Has $1.92 Million Position in Omnicell, Inc. $OMCL
Quantinno Capital Management LP significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 390.2%, now holding 57,560 shares valued at $1.92 million. This move comes as institutional investors collectively own 97.7% of the company, and analysts maintain a "Moderate Buy" rating despite recent price target adjustments. Omnicell recently surpassed earnings estimates with an EPS of $0.94 and a 7.4% year-over-year revenue increase.
(OMCL) Price Dynamics and Execution-Aware Positioning
Omnicell Inc. (NASDAQ: OMCL) is exhibiting choppy conditions due to divergent sentiment across all time horizons, with support currently being tested. The AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each tailored for different risk profiles. The analysis highlights an exceptional 72.8:1 risk-reward setup targeting a 20.3% gain versus 0.3% risk if support holds.
Millennium reports 3.8% Omnicell (OMCL) stake in amended 13G filing
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have collectively reported a beneficial ownership of 1,734,375 shares of Omnicell, Inc. (OMCL) common stock, which represents 3.8% of the outstanding class. This disclosure was made in an amended 13G filing, indicating shared voting and dispositive power over these shares, with no single entity holding sole control. The filing confirms their stake is below the 5% threshold, categorizing it as a passive investment.
Does Omnicell’s Profit Rebound And Higher 2026 Outlook Change The Bull Case For OMCL?
Omnicell, Inc. reported strong Q2 2026 results with increased revenue and net income, alongside upgraded guidance for the full year 2026. This improved profitability and higher revenue outlook strengthen the company's investment narrative, which relies on medication management automation and a growing software and services mix. However, the analysis also notes potential short-term risks from hospital budget pressures that could impact automation and SaaS adoption.
Omnicell (OMCL) Could Be 40% Undervalued Following Strong Q2 Earnings And Guidance Raised
Omnicell (OMCL) reported strong Q2 2026 earnings, leading to a rebound in its stock price and updated full-year revenue guidance. The company is considered undervalued by Simply Wall St's narrative, with a fair value of $61.29 compared to its current price of $36.81, driven by expectations of growth from its OmniSphere platform and a shift to higher-margin SaaS revenues. However, its P/E ratio is currently higher than the industry average, suggesting potential caution for investors.
Omnicell (NasdaqGS:OMCL) Stock Forecast & Analyst Predictions
This article provides an in-depth analysis of Omnicell's (OMCL) stock forecast and analyst predictions, highlighting expected earnings and revenue growth, key financial updates, and recent market activities. It covers various updates including earnings guidance, price target changes, leadership appointments, and new product launches like Omnicell Titan XT, alongside insider transactions and risk assessments. The report indicates a mixed analyst sentiment but generally points to future growth driven by new product cycles and an expanding service business.
First Trust Advisors LP Has $2.85 Million Stake in Omnicell, Inc. $OMCL
First Trust Advisors LP significantly reduced its stake in Omnicell, Inc. during the first quarter, selling over 46,000 shares but still retaining a $2.85 million position. Despite this reduction, institutional investors collectively own a substantial 97.7% of OMCL. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $57.86, following Omnicell's recent earnings beat.
Royal Bank of Canada Sells 78,803 Shares of Omnicell, Inc. $OMCL
Royal Bank of Canada reduced its stake in Omnicell, Inc. by 12.9%, selling 78,803 shares but still retaining 532,172 shares valued at approximately $17.8 million. Other institutional investors have also adjusted their positions, and Omnicell reported strong quarterly earnings, beating analyst estimates with a 7.4% year-over-year revenue increase. The company maintains a "Moderate Buy" consensus rating from analysts, despite a recent dip in its stock price.
OMNICELL, INC. 2026: Revenue $312.21M, EPS $0.52— 10-Q Summary
Omnicell, Inc. (OMCL) reported strong financial results for the quarter ended 2026, with revenue reaching $312.21M and diluted EPS of $0.52. This growth was driven by increased product and service sales, improved margins, and strategic shifts towards platform offerings and recurring revenue. The company also highlighted investments in R&D and expanded services to support long-term automation adoption.
OMCL|Omnicell Inc|Price:37.525|Chg%:+2.155
This article provides a comprehensive stock analysis of Omnicell Inc (OMCL), highlighting its relatively healthy fundamentals, significant growth potential, and fair valuation. Despite recent weak stock market performance, the company maintains strong fundamentals, and analysts have issued "Buy" ratings with a high price target. The report details Omnicell's business, key financial metrics, institutional ownership, and a peer comparison within the Healthcare Equipment & Supplies industry.
Weekly Recap: Omnicell, Inc. Q3/2026 revenue and analyst price target
Omnicell, Inc. (OMCL) reported Q3 revenue between $301-$307 million and guided 2026 revenue to $1.225-$1.245 billion, with an estimated year-end ARR of $660-$680 million. Analysts are optimistic, with a median 12-month price target of $60, suggesting a 31% upside, and the company recently appointed new executives including a President and COO.
Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability
Omnicell (OMCL) reported stronger Q2 2026 revenue and net income, alongside improved profitability for the first half of 2026. The company also raised its full-year 2026 revenue guidance to between US$1.23 billion and US$1.25 billion, signaling higher expectations. Despite the positive outlook, the stock declined by 12.5%, and the article discusses the investment narrative, risks from tariffs and hospital budgets, and varying analyst forecasts.
Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability
Omnicell (OMCL) reported strong second-quarter 2026 revenue and net income, showing improved profitability for the first half of the year. The company raised its full-year 2026 revenue guidance to US$1.23 billion to US$1.25 billion, reflecting management's higher expectations despite a 12.5% stock drop. This positive outlook is driven by anticipated growth in automation and software in healthcare, though risks like tariffs and hospital budget pressures remain.
Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability
Omnicell, Inc. (OMCL) reported improved financial results for Q2 2026, including increased revenue and a return to profitability, leading them to raise their full-year 2026 revenue guidance to US$1.23 billion to US$1.25 billion. Despite these positive developments, the stock price fell by 12.5%. The article discusses the investment narrative for Omnicell, emphasizing the reliance on hospital and pharmacy automation investment, while also considering risks like tariffs and hospital budget pressures, and analyst perspectives on future growth and profitability.
Omnicell Promotes Chief Operating Officer Nnamdi Njoku to President
Omnicell has promoted its Chief Operating Officer, Nnamdi Njoku, to President, expanding his role to include directing long-term growth, product development, and overseeing global operations. Njoku, who joined Omnicell less than two years ago, will also lead the launch of the Titan XT system and expansion of the OmniSphere platform. CEO Randall Lipps will focus more on customer relationships, strategic partnerships, and product portfolio development.
ETFs Investing in Omnicell, Inc. Stocks
This article lists various ETFs that hold Omnicell, Inc. (OC9) stocks, sorted by market value. It provides key details for each ETF, such as issuer, management style, focus, expense ratio, AUM, price, change, and 3-year NAV total return. The ETFs predominantly target small-cap and healthcare sectors, with some also focusing on themes like robotics and artificial intelligence.
